Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has initiated the human trial of ARO-ALK7, a novel RNA interference (RNAi) ...

Learn about May 2025’s top biotech deals, featuring major collaborations in RNA interference technology, small molecules, and ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-ALK7, the company’s investigational RNA interference (RNAi) ...

The expression of symptoms of viral infections is a byproduct of complex virus-host molecular pathways. These remain largely ...

A startup seeking to replace animal testing with a sophisticated high-tech platform has raised $40 million to develop ...

In summary, zilebesiran shows great promise as a long-acting treatment for high blood pressure. If future trials confirm its ...

CM, offers strong efficacy and a favorable safety profile compared to competitors. See why I rate ALNY stock a Hold.

Arrowhead Pharmaceuticals, Inc.'s deal with Sarepta expands its pipeline, but limited plozasiran market and competition ...

A start-up that launched only 8 months ago has attracted the attention of Biogen, a major developer of neurological drugs.

Rona Therapeutics Co. Ltd. has reported preclinical data for its RNA interference (RNAi) therapy RN-026 targeting lipoprotein(a) (Lp[a]).

Results from a clinical trial led by researchers from Queen Mary University of London, published today in JAMA, show that ...

A surge in clinical trials investigating potential idiopathic pulmonary fibrosis therapies offers patients new hope, ...